RP-6306 Combination Therapy for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing RP-6306, a new drug, to see if it can help treat cancer when used with standard treatments. It focuses on patients with specific biomarkers to see if they respond better. The drug works by blocking a protein that helps cancer cells grow.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but you cannot take proton pump inhibitors, strong CYP3A inhibitors, or inducers during the trial. There is also a washout period (time without taking certain medications) required for previous chemotherapy or systemic therapy.
What makes the drug RP-6306 unique for cancer treatment?
Research Team
Stephanie Lheureux
Principal Investigator
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Yvette Drew
Principal Investigator
BCCA-Vancouver Cancer Centre, Vancouver BC Canada
Eric Chen
Principal Investigator
University Health Network, Princess Margaret Hospital, Toronto ON Canada
Eligibility Criteria
Adults with advanced cancers like endometrial, NSCLC, ovarian carcinosarcoma, TNBC, PDAC, colorectal cancer or HER-2+ gastroesophageal cancer. They must have tried some treatments already (like platinum-based chemotherapy), be in good physical condition and expected to live at least 3 months. Specific genetic markers are required for some cohorts. Pregnant women and those with certain health conditions or previous hypersensitivity to study drugs can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RP-6306 in combination with standard treatments such as Trastuzumab, RP-3500, Gemcitabine, or FOLFIRI
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- RP-6306
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
Repare Therapeutics
Industry Sponsor